These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 27376492)

  • 1. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
    Pires ADRA; Lecerf-Schmidt F; Guragossian N; Pazinato J; Gozzi GJ; Winter E; Valdameri G; Veale A; Boumendjel A; Di Pietro A; Pérès B
    Eur J Med Chem; 2016 Oct; 122():291-301. PubMed ID: 27376492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
    Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
    Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
    Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
    J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
    Winter E; Lecerf-Schmidt F; Gozzi G; Peres B; Lightbody M; Gauthier C; Ozvegy-Laczka C; Szakacs G; Sarkadi B; Creczynski-Pasa TB; Boumendjel A; Di Pietro A
    J Med Chem; 2013 Dec; 56(24):9849-60. PubMed ID: 24304387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
    Krapf MK; Gallus J; Wiese M
    Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.
    Payen L; Honorat M; Guitton J; Gauthier C; Bouard C; Lecerf-Schmidt F; Peres B; Terreux R; Gervot H; Rioufol C; Boumendjel A; Puisieux A; Di Pietro A
    Oncotarget; 2014 Dec; 5(23):11957-70. PubMed ID: 25474134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
    Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
    J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2.
    Roussel E; Tran-Nguyen VK; Bouhedjar K; Dems MA; Belaidi A; Matougui B; Peres B; Azioune A; Renaudet O; Falson P; Boumendjel A
    Eur J Med Chem; 2019 Dec; 184():111772. PubMed ID: 31630055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.
    Boumendjel A; Macalou S; Ahmed-Belkacem A; Blanc M; Di Pietro A
    Bioorg Med Chem; 2007 Apr; 15(8):2892-7. PubMed ID: 17317193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
    Kraege S; Stefan K; Juvale K; Ross T; Willmes T; Wiese M
    Eur J Med Chem; 2016 Jul; 117():212-29. PubMed ID: 27100033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
    Köhler SC; Vahdati S; Scholz MS; Wiese M
    Eur J Med Chem; 2018 Feb; 146():483-500. PubMed ID: 29407974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
    Krapf MK; Wiese M
    J Med Chem; 2016 Jun; 59(11):5449-61. PubMed ID: 27148793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCG2: recent discovery of potent and highly selective inhibitors.
    Lecerf-Schmidt F; Peres B; Valdameri G; Gauthier C; Winter E; Payen L; Di Pietro A; Boumendjel A
    Future Med Chem; 2013 Jun; 5(9):1037-45. PubMed ID: 23734686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.
    Hénin E; Honorat M; Guitton J; Di Pietro A; Payen L; Tod M
    Biopharm Drug Dispos; 2017 Jul; 38(5):351-362. PubMed ID: 28207160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein.
    Valdameri G; Genoux-Bastide E; Gauthier C; Peres B; Terreux R; Winnischofer SM; Rocha ME; Di Pietro A; Boumendjel A
    ChemMedChem; 2012 Jul; 7(7):1177-80. PubMed ID: 22615192
    [No Abstract]   [Full Text] [Related]  

  • 17. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
    Anreddy N; Patel A; Zhang YK; Wang YJ; Shukla S; Kathawala RJ; Kumar P; Gupta P; Ambudkar SV; Wurpel JN; Chen ZS; Guo H
    Oncotarget; 2015 Nov; 6(36):39276-91. PubMed ID: 26515463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates.
    Kraege S; Stefan K; Köhler SC; Wiese M
    ChemMedChem; 2016 Nov; 11(22):2547-2558. PubMed ID: 27785905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
    Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
    Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The More the Better-Investigation of Polymethoxylated
    Stockmann P; Kuhnert L; Leinung W; Lakoma C; Scholz B; Paskas S; Mijatović S; Maksimović-Ivanić D; Honscha W; Hey-Hawkins E
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.